Tradestie Institutional Equity Comparison Engine

NVS vs GSK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NVS Overall Edge

NVS Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Novartis AG (NVS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GSK counters with relative strength in Valuation. Fundamentally, NVS trades at 16.2x Forward P/E with 34.0% operating margin (+4.7% YoY revenue) versus GSK at 10.2x Forward P/E and 30.5% operating margin (+4.0% YoY). In options structure, NVS sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro) against GSK sits in UNCLASSIFIED (39th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GSK
NVS 16.2x vs GSK 10.2x Fwd P/E
Growth & Margin Winner NVS
Op Margin 34.0% vs 30.5% ยท YoY +4.7% vs +4.0%
Momentum & Technical Winner NVS
1Y +22.5% vs +5.5% ยท 52W Pos 81% vs 31%
Options & Structure Winner NVS
UNCLASSIFIED (6th %ile IV) vs UNCLASSIFIED (39th %ile IV)
NVS NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
1M Return +7.28%
1Y Return +22.5%
Forward P/E 16.2x
Unified AI Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
GSK NYSE
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Pharmaceutical Preparations
$50.77
+0.63% 1D
Market Cap $101.5B
1M Return +2.54%
1Y Return +5.46%
Forward P/E 10.2x
Unified AI Score
42.7 / 100 HOLD
Tech 41.0 Fund 38.0 Flow 50.0 Mom 11.5

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NVS +22.5% GSK +5.46% Spread: +17.04 pp (NVS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NVS TTM Op. Margin: 34.0% GSK TTM Op. Margin: 30.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs GSK. Trailing 12-month operating profitability (NVS 34.0% vs GSK 30.5%) and valuation multiples (NVS 16.2x vs GSK 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NVS (6) vs GSK (4)
Institutional Metric NVS GSK Criterion Row Winner
Market Capitalization Scale $302.9B $101.5B Larger Scale NVS
Trailing P/E Ratio Valuation 30.6x 17.6x Lower Multiple GSK
Forward P/E Ratio Valuation 16.2x 10.2x Lower Multiple GSK
Revenue Growth (YoY) Growth +4.7% +4.0% Higher Growth NVS
Operating Margin (TTM) Profitability 34.0% 30.5% Higher Margin NVS
Net Profit Margin Profitability 17.5% 13.0% Higher Margin NVS
Return on Equity (ROE) Capital Efficiency 24.3% 28.3% Higher ROE GSK
52-Week Range Position Momentum 81% ($123โ€“$170) 31% ($46โ€“$62) Stronger Trend NVS
Beta / 30D Volatility Risk Regime 0.31ฮฒ ยท 27% Vol 0.27ฮฒ ยท 30% Vol Lower Realized Risk NVS
Unified Institutional Score Composite Signal 41.5 / 100 (SELL) 42.7 / 100 (HOLD) Higher Composite GSK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NVS vs GSK Buy Guide
NVS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live NVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GSK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 39th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live GSK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NVS nor GSK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.